Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference.

Andy Sheldon - President and Chief Executive Officer

Louis-Philippe Vézina, Ph.D - Chief Scientific Officer

Pierre Labbé, Chartered Accountant - Vice President and Chief Financial Officer

Frederic Ors, B.Sc., M.A. - Vice-President, Business development

Nathalie Landry, M.Sc., MBA - Vice-President, Product Development

Irene Clement - Vice-President, Regulatory affairs

Brigitte Barbeau, B. Sc. - Vice-President, Manufacturing

Dr. Randal Chase - Chairman of the Board

Mr. Pierre Des Marais II, O.C. - Director

Mr. Jonathan R. Goodman - Director

Mr. Pierre Marc Johnson - Director

Mr. Pierre Seccareccia - Director

Mr. Andrew J. Sheldon - Director

Dr. Louis Philippe Vézina - Director